Teva Pharmaceutical Industries Cash on Hand 2010-2024 | TEVA
Teva Pharmaceutical Industries cash on hand from 2010 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
- Teva Pharmaceutical Industries cash on hand for the quarter ending June 30, 2024 was $2.258B, a 15.4% decline year-over-year.
- Teva Pharmaceutical Industries cash on hand for 2023 was $3.226B, a 15.17% increase from 2022.
- Teva Pharmaceutical Industries cash on hand for 2022 was $2.801B, a 29.38% increase from 2021.
- Teva Pharmaceutical Industries cash on hand for 2021 was $2.165B, a 0.55% decline from 2020.
Teva Pharmaceutical Industries Annual Cash on Hand
(Millions of US $) |
| 2023 |
$3,226 |
| 2022 |
$2,801 |
| 2021 |
$2,165 |
| 2020 |
$2,177 |
| 2019 |
$1,975 |
| 2018 |
$1,782 |
| 2017 |
$963 |
| 2016 |
$988 |
| 2015 |
$6,946 |
| 2014 |
$2,226 |
| 2013 |
$1,038 |
| 2012 |
$2,879 |
| 2011 |
$1,096 |
| 2010 |
$1,248 |
| 2009 |
$2,248 |
Teva Pharmaceutical Industries Quarterly Cash on Hand
(Millions of US $) |
| 2024-06-30 |
$2,258 |
| 2024-03-31 |
$2,991 |
| 2023-12-31 |
$3,226 |
| 2023-09-30 |
$2,249 |
| 2023-06-30 |
$2,669 |
| 2023-03-31 |
$2,143 |
| 2022-12-31 |
$2,801 |
| 2022-09-30 |
$2,225 |
| 2022-06-30 |
$2,058 |
| 2022-03-31 |
$2,175 |
| 2021-12-31 |
$2,165 |
| 2021-09-30 |
$2,045 |
| 2021-06-30 |
$2,436 |
| 2021-03-31 |
$1,743 |
| 2020-12-31 |
$2,177 |
| 2020-09-30 |
$1,827 |
| 2020-06-30 |
$2,402 |
| 2020-03-31 |
$1,804 |
| 2019-12-31 |
$1,975 |
| 2019-09-30 |
$1,241 |
| 2019-06-30 |
$2,165 |
| 2019-03-31 |
$1,973 |
| 2018-12-31 |
$1,782 |
| 2018-09-30 |
$1,875 |
| 2018-06-30 |
$1,861 |
| 2018-03-31 |
$1,418 |
| 2017-12-31 |
$963 |
| 2017-09-30 |
$680 |
| 2017-06-30 |
$599 |
| 2017-03-31 |
$900 |
| 2016-12-31 |
$988 |
| 2016-09-30 |
$2,614 |
| 2016-06-30 |
$6,984 |
| 2016-03-31 |
$5,964 |
| 2015-12-31 |
$6,946 |
| 2015-09-30 |
$928 |
| 2015-06-30 |
$1,068 |
| 2015-03-31 |
$3,396 |
| 2014-12-31 |
$2,226 |
| 2014-09-30 |
$1,473 |
| 2014-06-30 |
$949 |
| 2014-03-31 |
$901 |
| 2013-12-31 |
$1,038 |
| 2013-09-30 |
$1,148 |
| 2013-06-30 |
$1,245 |
| 2013-03-31 |
$1,394 |
| 2012-12-31 |
$2,879 |
| 2012-09-30 |
$1,432 |
| 2012-06-30 |
$1,188 |
| 2012-03-31 |
$1,062 |
| 2011-12-31 |
$1,096 |
| 2011-09-30 |
$1,123 |
| 2011-06-30 |
$1,157 |
| 2011-03-31 |
$748 |
| 2010-12-31 |
$1,248 |
| 2010-09-30 |
$956 |
| 2010-06-30 |
$4,878 |
| 2010-03-31 |
$2,693 |
| 2009-12-31 |
$2,248 |
| 2009-09-30 |
$1,778 |
| 2009-06-30 |
$1,803 |
| 2009-03-31 |
$2,400 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$20.902B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
